ADC Therapeutics SA
Company Stats
- Market Cap
- $155.8M
- as of Sep 30, 2026
- Shares Outstanding
- 127.7M
- Free Float
- 62.3%
Income Statement
- Revenue
- $81.4M
- Operating Income
- -$121.5M
- Net Income
- -$142.6M
- EBITDA
- -$120.8M
- Non-cash Impairment
- $5.0M
- Revenue Growth, 3Y
- -27.1%
- FCF Margin, 3Y Avg
- -175.0%
- FCF Margin, Worst Year
- -176.0%
Cash Flow
- Free Cash Flow
- -$141.4M
- FCF Yield
- -90.8%
- Owner FCF Yield
- -95.2%
Balance Sheet
- Cash & Equivalents
- $261.3M
Returns & Capital
- SBC, 3Y Avg
- $9.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $81.4M | -$141.4M | -173.8% |
| FY2024 | $70.8M | -$124.7M | -176.0% |
| FY2023 | $69.6M | -$121.9M | -175.3% |
| FY2022 | $209.9M | -$139.0M | -66.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges